
Contrave Extended-Release
Naltrexone Hydrochloride And Bupropion Hydrochloride
- SKU
- 51267-890
- UPC
- 0351267890997
- Mfr
- Nalpropion Pharmaceuticals LLC
120 tablet, extended release in 1 bottle
$398.00
2 packs × $199.00 each
Minimum order: 2 packs. Each product is sold in quantities worth at least $300.00.
Prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it. How it works
CONTRAVE is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition.
- Strength
- Naltrexone Hydrochloride 8 mg/1, Bupropion Hydrochloride 90 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet, Extended Release
- Route
- Oral
Pharmacologic class
- AminoketoneEstablished class
- Dopamine Uptake InhibitorsMechanism
- Increased Dopamine ActivityPhysiologic effect
- Increased Norepinephrine ActivityPhysiologic effect
- Norepinephrine Uptake InhibitorsMechanism
- Opioid AntagonistEstablished class
- Opioid AntagonistsMechanism
- Brand name
- Contrave Extended-Release
- Generic name
- Naltrexone Hydrochloride And Bupropion Hydrochloride
- Manufacturer
- Nalpropion Pharmaceuticals LLC
- Product NDC (SKU)
- 51267-890
- UPC
- 0351267890997
- Active ingredients
- Naltrexone Hydrochloride 8 mg/1, Bupropion Hydrochloride 90 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet, Extended Release
- Route
- Oral
- DEA schedule
- Not controlled
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application number
- NDA200063
- Marketed since
- October 22, 2014
- Label revised
- November 10, 2025
| Package NDC | Description |
|---|---|
| 51267-890-07 | 7 TABLET, EXTENDED RELEASE in 1 BOTTLE |
| 51267-890-99 | 120 TABLET, EXTENDED RELEASE in 1 BOTTLE |
Reading this NDC
51267-890-07
- 01Labeler code
- Nalpropion Pharmaceuticals LLC
- 02Product code
- Contrave Extended-Release, tablet, extended release
- 03Package code
- 7 tablet, extended release in 1 bottle
CONTRAVE has two components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Nonclinical studies suggest that naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system). The exact neurochemical effects of CONTRAVE leading to weight loss are not fully understood.
Warning: Suicidal thoughts and behaviors warning: suicidal thoughts and behaviors
See full prescribing information for complete boxed warning Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders.
Monitor for worsening and emergence of suicidal thoughts and behaviors.
CONTRAVE is not approved for use in pediatric patients.
SUICIDALITY AND ANTIDEPRESSANT DRUGS CONTRAVE ® is not approved for use in the treatment of major depressive disorder or other psychiatric disorders. CONTRAVE contains bupropion, the same active ingredient as some antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, and APLENZIN). Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials.
These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on CONTRAVE, monitor closely for worsening, and for the emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.
CONTRAVE is not approved for use in pediatric patients [see Warnings and Precautions
, Use in Specific Populations
].
CONTRAVE is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition. CONTRAVE is a combination of naltrexone, an opioid antagonist, and bupropion, an aminoketone antidepressant, indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition.
Limitations of Use. The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established.
Coadministration with other naltrexone-containing products is not recommended. Coadministration with other bupropion-containing products is contraindicated.
Limitations of Use. The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. CONTRAVE contains naltrexone and bupropion. Coadministration with other naltrexone-containing products is not recommended. Coadministration with other bupropion-containing products is contraindicated.
Read before you order

Weight management · 2 min read
Orlistat, phentermine and Contrave: the older weight-loss medicines
How orlistat, phentermine and naltrexone-bupropion work, who they suit and the side effects to know about before starting.

Weight management · 3 min read
How GLP-1 weight-loss medicines work
Semaglutide, tirzepatide and liraglutide explained: how they reduce appetite, how quickly they work and what to expect in the first months.

Weight management · 2 min read
Managing nausea and other GLP-1 side effects
Practical ways to cope with nausea, constipation and reflux on semaglutide or tirzepatide, and the warning signs that need a doctor.
More in Weight Management
View all
Brand · Capsule
Alli
Orlistat 60 mg/1
- SKU
- 0135-0461
- Mfr
- Haleon US Holdings LLC
From $47.99Min. 7 packs

Brand · Capsule
Alli
Orlistat 60 mg/1
- SKU
- 71610-805
- Mfr
- Aphena Pharma Solutions - Tennessee, LLC
From $1,329.43

Brand · Injection
Mounjaro
Tirzepatide 4.17 mg/mL
- SKU
- 0002-4052
- Mfr
- Eli Lilly and Company
From $1,454.99

Brand · Injection
Mounjaro Kwikpen
Tirzepatide 20.8 mg/mL
- SKU
- 0002-3422
- Mfr
- Eli Lilly and Company
From $1,454.99